$AFJK
Aimei Health Technology Co., Ltd.

2024 Q2 Form 10-Q Financial Statement

#000149315224018883 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $309.1K $153.6K
YoY Change
Operating Profit
YoY Change
Interest Expense $918.2K $909.1K
YoY Change
% of Operating Profit
Other Income/Expense, Net $918.2K $909.1K
YoY Change
Pretax Income $609.1K $755.5K
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $609.1K $755.5K
YoY Change -16935.05%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.07 $0.08
COMMON SHARES
Basic Shares Outstanding 9.026M shares 9.026M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.5K $413.8K
YoY Change
Cash & Equivalents $157.5K $413.7K $580.7K
Short-Term Investments
Other Short-Term Assets $46.84K $66.67K
YoY Change
Inventory
Prepaid Expenses $46.84K $66.67K
Receivables
Other Receivables
Total Short-Term Assets $204.3K $480.7K $580.7K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $71.72M $70.80M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $71.72M $70.80M $69.89M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $204.3K $480.7K $580.7K
Total Long-Term Assets $71.72M $70.80M $69.89M
Total Assets $71.92M $71.28M $70.47M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $59.41K $78.47K $24.84K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $111.2K $78.47K $24.84K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $690.0K $690.0K
YoY Change
Total Long-Term Liabilities $690.0K $690.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $111.2K $78.47K $24.84K
Total Long-Term Liabilities $690.0K $690.0K
Total Liabilities $801.2K $768.5K $714.8K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$597.1K -$288.0K -$134.3K
YoY Change
Common Stock $213.00 $213.00 $213.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$596.9K -$287.8K -$134.1K
YoY Change
Total Liabilities & Shareholders Equity $71.92M $71.28M $70.47M
YoY Change

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income $609.1K $755.5K
YoY Change -16935.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$256.2K -$167.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -256.2K -$167.0K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -256.2K -$167.0K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$256.2K -$167.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41880
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
AIMEI HEALTH TECHNOLOGY CO., LTD.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023Q4 us-gaap Cash
Cash
580717 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
66667 usd
CY2024Q1 us-gaap Other Receivables
OtherReceivables
302 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24841 usd
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
690000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
714841 usd
CY2024Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6900000 shares
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6900000 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2024Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.26
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.13
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
69889848 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
213 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134337 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-134124 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70470565 usd
CY2024Q1 us-gaap Investment Income Dividend
InvestmentIncomeDividend
909132 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
909132 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
755500 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-134124 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-134124 usd
CY2024Q1 AFJK Remeasurement Of Carrying Value To Redemption Value
RemeasurementOfCarryingValueToRedemptionValue
-909132 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
755500 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-287756 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-287756 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
755500 usd
CY2024Q1 AFJK Interest Earned On Investments Held In Trust
InterestEarnedOnInvestmentsHeldInTrust
909132 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
66667 usd
CY2024Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
302 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
53631 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-166970 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-166970 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
580717 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
413747 usd
CY2024Q1 AFJK Remeasurement Of Carrying Value To Redemption Values
RemeasurementOfCarryingValueToRedemptionValues
909132 usd
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2023-04-27
CY2024Q1 AFJK Business Combination Description
BusinessCombinationDescription
If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining holders of ordinary shares and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2024Q1 us-gaap Share Price
SharePrice
10.10
CY2024Q1 us-gaap Cash
Cash
413747 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
70798980 usd
CY2024Q1 AFJK Working Capital
WorkingCapital
402244 usd
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
5000001 usd
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_z0NQtm7lowQd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86B_znMJ3IGZkqn9">Use of estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed as of the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
70798980 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
69889848 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
755500 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zamvZqNg5P3d" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">●</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_865_z1LXpXMrgoh4">Concentration of credit risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zcU9MSqobIB" title="FDIC insured amount">250,000</span>. As of March 31, 2024 and December 31, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. As of March 31, 2024 and December 31, 2023, $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20240331_zUgdX5E5TPm4" title="FDIC uninsured amount">163,747</span> and $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20231231_zDRhdDJX5kj5" title="FDIC uninsured amount">330,717</span> was not insured, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
163747 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
330717 usd
CY2024Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
70798980 usd
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
69889848 usd
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
30000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
10000 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
25000 usd
CY2023Q3 us-gaap Cash
Cash
25000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares

Files In Submission

Name View Source Status
0001493152-24-018883-index-headers.html Edgar Link pending
0001493152-24-018883-index.html Edgar Link pending
0001493152-24-018883.txt Edgar Link pending
0001493152-24-018883-xbrl.zip Edgar Link pending
afjk-20240331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
afjk-20240331_def.xml Edgar Link unprocessable
afjk-20240331_pre.xml Edgar Link unprocessable
afjk-20240331_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
afjk-20240331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable